Agios to Webcast Conference Call of Fourth Quarter and Year End 2021 Financial Results on Feb. 24, 2022
Agios Pharmaceuticals (NASDAQ: AGIO) will host a conference call and live webcast on February 24, 2022, at 8:00 a.m. ET to discuss its Q4 and year-end 2021 financial results. The event highlights Agios's commitment to transparency and communication with its investors. Interested parties can access the live webcast via the company’s website under the 'Events & Presentations' section. Agios is known for its innovative therapies targeting genetically defined diseases, especially in cellular metabolism and hemolytic anemias.
- Agios is advancing a robust pipeline of investigational medicines, including a first-in-class pyruvate kinase activator.
- The company maintains strong relationships with patient communities and healthcare professionals, enhancing its market presence.
- None.
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced the company will host a conference call and live webcast on Thursday, Feb. 24, 2022, at 8:00 a.m. ET to report its fourth quarter and year end 2021 financial results and other business highlights.
A live webcast can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. The conference call can be accessed by dialing 1-877-377-7098 (domestic) or 1-631-291-4547 (international) and referring to conference ID 9873227. The webcast will be archived and made available for replay on the company's website beginning approximately two hours after the event.
About Agios
Agios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver therapies for genetically defined diseases. Building on the company's leadership in the field of cellular metabolism, Agios is advancing a robust pipeline of investigational medicines, including a first-in-class pyruvate kinase (PK) activator that is being evaluated for the treatment of three distinct hemolytic anemias – pyruvate kinase deficiency, alpha- and beta-thalassemia and sickle cell disease. In addition to its active late-stage clinical pipeline, Agios has multiple novel investigational therapies in clinical and preclinical development. For more information, please visit the company’s website at www.agios.com.
Contacts
Investors:
Holly Manning, 617-844-6630
Senior Director, Investor Relations
Holly.Manning@agios.com
Media:
Jessica Rennekamp, 857-209-3286
Director, Corporate Communications
Jessica.Rennekamp@agios.com
FAQ
What will Agios Pharmaceuticals announce on February 24, 2022?
How can I access the Agios Pharmaceuticals conference call?
What is the focus of Agios Pharmaceuticals?
Where can I find the Agios Pharmaceuticals live webcast?
